Company news

Kymera Therapeutics, Inc. news in 2023

Kymera Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4

December 12, 2023

Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting

December 9, 2023

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi

December 6, 2023

Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine

November 12, 2023

Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting

November 1, 2023

Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update

November 1, 2023

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi

October 26, 2023

Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2

October 25, 2023

Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma

October 15, 2023

Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma

September 17, 2023

Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update

August 2, 2023

Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3

July 26, 2023

Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia

June 21, 2023

Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials

June 13, 2023

Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Models at the European Hematology Association Congress

June 8, 2023

Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413

June 8, 2023

Kymera Therapeutics to Participate in Upcoming June Investor Conference

May 31, 2023

Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer

May 21, 2023

Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253

May 18, 2023

Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium

May 17, 2023

Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update

May 3, 2023

Kymera Therapeutics to Report First Quarter 2023 Financial Results on May 4

April 10, 2023

Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update

February 22, 2023

Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23

January 31, 2023

X-Chem and Kymera Expand Existing Partnership

January 30, 2023

Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company

January 9, 2023

Kymera Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary

January 3, 2023

Kymera Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023

January 2, 2023

Calls in 2023

Decks in 2023